Treatment with the Food and Drug Administration-approved, EGFR-specific tyrosine kinase inhibitor, Erlo, resulted in a reduction of HEV p6, 83-2 and enveloped p6 infection events by ~76%, 99%, and 97%, respectively. This evidence concerns the gene EGFR and infection.